{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"To estimate the proportion of participants achieving a disease-specific response following curcumin and piperine supplementation administered at a dose of 2gm/10mg(2 tablets) orally twice daily for up to 12 months.\n\nFor patients with early-stage prostate cancer, response was defined as ≥50% decrease in prostate-specific antigen (PSA) from baseline, confirmed at least 4 weeks apart.\n\nFor patients with MGUS or low-risk SMM, response was defined per International Myeloma Working Group (IMWG) criteria as at least a partial response (≥50% reduction in serum M-protein).\n\nThe overall response rate equals the number of participants achieving disease-specific response divided by total number analyzed.","groups":[{"description":"Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months\n\nCurcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.","id":"OG000","title":"Prostate Cancer"},{"description":"Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months\n\nCurcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.","id":"OG001","title":"Smoldering Multiple Myeloma (SMM)"},{"description":"Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months\n\nCurcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.","id":"OG002","title":"Monoclonal Gammopathy of Unknown Significance (MGUS)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All enrolled participants","reportingStatus":"POSTED","timeFrame":"From date of enrollment until the date of first documented response assessed up to 12 months","title":"Response Rate of Curcumin & Piperine Supplementation in Patients on Active Surveillance for Either Early Stage Prostate Cancer or Patients on Observation for MGUS/Low-risk Smoldering Myeloma.","type":"PRIMARY","unitOfMeasure":"Participants"}